8th Annual Chfr Symposium

COVER 8th Annual Chfr Symposium Program and ABSTRACTS September 30 October 01, 2010

Center for Heart Failure Research 20ı0 Dear Participant, We are very pleased to welcome you to the 8th Annual CHFR Symposium. We look forward to a very exciting meeting, fruitful discussions and scientific interactions. The Center for Heart Failure Research constitutes a branch of medical research within the Faculty of Medicine at the University of. It is financially supported by the University and the South-Eastern Norway Regional Health Authority (Helse Sør-Øst). The Center represents the concerted action of groups with complementary expertise combining state-ofthe-art gene technology and capabilities to investigate protein function in experimental systems. The systems range from isolated cells and multicellular preparations to integrative physiology in pathophysiological models of heart failure. The clinical research groups of the Center for Heart Failure Research allow for testing of hypotheses in prospective clinical studies. The Center also organizes the PhD School of Heart Research that provides a high quality program specifically aimed at qualifying PhD students for future careers in heart research. The School hosts an annual introductory course as well as workshops for ongoing projects, and it provides a network for collaborations and exchange of methods and ideas within the Center. The Center also organizes the required mid-term evaluation (midtveisevaluering) of the PhD candidates in the field of heart research. We are happy to announce that the is sponsored by the Anders Jahre s Fund for Promotion of Science. Our main aim is to promote and integrate high quality research from bench to bedside in the field of heart failure. Steering committee, Center for Heart Failure Research Geir Øystein Andersen, Harald Arnesen, Dan Atar, Håvard Attramadal, Reidar Bjørnerheim, Thor Edvardsen, Lars Gullestad, John Kjekshus, Finn Olav Levy, Torbjørn Omland, Jan-Bjørn Osnes, Ole M. Sejersted, Ingebjørg Seljeflot, Ivar Sjaastad, Tor Skomedal, Otto Smiseth, Petter Andreas Steen, Guro Valen and Geir Christensen Organizers: Fredrik Swift, Mathis Stokke, Anne Wæhre Page 2

Content 04 General information 06 Information for speakers and poster presenters 07 Program 09 Poster sessions 15 Abstracts Poster session I 25 Abstracts Poster session II 36 Abstracts Poster session III 48 Abstracts Poster session IV 59 Abstracts Poster session V 71 List of participants Page 3

General information Venue All events take place at, Oslo (www.holmenkollenparkhotel.no). The hotel is nicely located 350 m above sea level, overlooking Oslo. The scientific sessions are held in Saga Hall. Registration On the first day of the meeting please collect your badge and program at the registration desk as soon as possible upon arrival. The registration desk is located near Saga Hall. How to get there? By car: Eı8 South-west (from Drammen/Sandvika): Follow the signs to Ring 3 and Smestad. At Smestad, follow the signs to Holmenkollen. E6/Eı8 South-east (from Gothenburg/Stockholm): Follow the signs to Drammen, through Oslo city centre. Then follow the signs to Ring 3 and Smestad. At Smestad, follow the signs to Holmenkollen. E6 North (Oslo Airport, Gardermoen): After passing the toll booths, keep to the right and head towards Ring 3 Sinsen and Smestad. At Smestad, follow the signs to Holmenkollen. Parking: The hotel offers free parking in designated parking spots before the final approach to the hotel, in addition to indoor parking for a fee in the hotel s parking garage. Price: NOK 20,- per hour, NOK ı50,- per day. With public transport: Attention: Alternative transport by bus from Majorstuen due to construction work on the metro line to Holmenkollen. See below and www.ruter.no. From the airport: Upon arrival at Oslo Airport, Gardermoen, you can take the Airport Train directly to Oslo Central Station (Oslo S); trains depart every ı0 minutes. Travel time is approximately 20 minutes, and the cost is NOK ı70.00 From the Central Station (Oslo S): Take the metro (T-bane) to Majorstuen. From Majorstuen, bus ıb will take you to Holmenkollen T. Follow the road uphill towards the Holmenkollen National Ski Stadium. It is a ı0 minute walk, and slightly uphill. Taxi from the Central Station (Oslo S): The taxi journey takes approx 20 minutes, and the cost is NOK ı50 250, depending on what time you will be travelling and number of passengers. Airport Taxi: To get special prices by taxi from the Gardermoen Airport directly to the, just contact the Airport Taxi stand, next to the arrival gate inside or pre-order at: +47 02323. Page 4

Coffee Coffee, tea and soft drinks will be available in the lobby during breaks. Lunch Lunch is offered on both days of the meeting in Galleriet close to the main entrance. Refund of travel expenses (for invited speakers, chairs and moderators only) Your travel expenses and the costs for the hotel room in Oslo during the meeting will be covered by CHFR. We will pay for your stay at the hotel directly. Please make your own arrangements for flights and transport to/from the airport. For a refund of your travel expenses, please fill out the Refund of travel expenses form downloadable at http://www.heartfailure.no/resources/. If your travel costs have been paid by your university or employer, the refund must be given to them. In that case, please ask your employer to send us an invoice for the amount to be refunded. It is compulsory that you provide the IBAN number or bank code of your bank as well as your date of birth. It is also important that you provide the original bills, tickets, etc. Please keep a photocopy of these documents for your own record. The completed forms and the original receipts should be sent to the following address within 2 weeks after the meeting: Elisabeth Engh Seland Det teologiske fakultet Postboks ı023 Blindern N-03ı5 Oslo Norway Page 5

Information for speakers and posters presenters Oral presentations Please leave no less than 5 min at the end of your talk for discussion. We ask you to prepare your presentation in PowerPoint. A Windows computer with PowerPoint 2007 installed will be on-site. You must bring your presentation on a USB memory stick or CD at least one hour before your presentation starts. Alternatively, you can e-mail your presentation to fredrik.swift@medisin.uio.no before September 29, at ı8:00 (Central European Time). If you have any questions regarding the electronic presentations, or if you wish to verify the compatibility of your presentation, please contact: Fredrik Swift fredrik.swift@medisin.uio.no Phone: +47 48244250 Portrait ı20 x 90 cm Recommended poster size Poster categories: I: Inflammatory mediators and extracellular matrix in heart failure II: Cellular signaling, myocardial hypertrophy and ischemia III: Cellular signaling: myocardial dysfunction IV: Cardiac imaging and arrhythmias V: Markers of cardiovascular disease Poster presentations Posters will be mounted with push-pins, which will be available on-site. Please mount your posters on Thursday morning and according to the number assigned in the program. After the moderated poster sessions, the poster boards will be transferred to the area close to Saga Hall. Please leave your posters mounted until the end of the meeting. The poster should be presented orally in maximally 3 minutes followed by 4-5 minutes discussion. Please do not exceed this time in your presentation since there is only a limited time available for the moderated poster sessions. We encourage you to continue the discussion of the posters in Saga Hall during the breaks of the meeting. A prize of NOK 5000,- will be awarded to the author of the best poster in each session. The criteria are: ı) Novelty of conclusions. 2) Quality of data. 3) Clarity of presentation (purpose, results, conclusions). Page 6

Program SEPTEMBER 30, 20ı0 08:00-08:20 Registration 08:20-08:30 Welcome: Geir Christensen, OUHU, UoO Session A: 08:30-09:ı0 09:ı0-09:50 09:50-ı0:05 Cardiomyopathy and inflammation in heart failure Chairs: Otto Smiseth, OUHR, UoO and Theis Tønnessen, OUHU, UoO Christine Seidman, Harvard Medical School, Boston, Massachusetts, USA Cardiomyopathy: From mutation to mechanism Douglas L. Mann, Washington University in St. Louis, Missouri, USA Innate immunity and the failing heart: For whom the cell tolls Break Session B: Moderated poster sessions (ı0:05-ıı:30) I: Inflammatory mediators and extracellular matrix in heart failure Moderators: Arne Yndestad, OUHR and Ingebjørg Seljeflot, OUHU, UoO II: III: IV: Cellular signaling; myocardial hypertrophy and ischemia Moderators: Theis Tønnessen, OUHU, UoO and Terje Larsen, UoT Cellular signaling; myocardial dysfunction Moderators: Øyvind Ellingsen, NTNU and Ivar Sjaastad, OUHU, UoO Cardiac imaging and arrhythmias Moderators: Reidar Bjørnerheim, OUHU and Thor Edvardsen, OUHR, UoO V: Markers of cardiovascular disease Moderator: Helge Røsjø, AUH and Erik Øie, OUHR, Diakonhjemmet Hospital ıı:30-ı2:30 Lunch _ Session C: ı2:30-ı2:50 ı2:50-ı3:30 ı3:30-ı4:00 Publication issues and novel therapeutical approaches Chairs: Dan Atar, OUHU, UoO and Leif Erik Vinge, OUHR Thomas F. Lüscher, University Hospital Zürich, Switzerland How does the ESC journal family cover and prioritize the topic heart failure? Eva van Rooij, miragen Therapeutics, Inc., Boulder, Colorado, USA Oligo-based modulation of mirnas to control cardiovascular disease Break Session D: ı4:00-ı4:40 Vascular disease and cardiac dysfunction Chairs: Harald Arnesen, OUHU, UoO and Thor Edvardsen, OUHR, UoO Boaz D. Rosen, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA Indicators of early myocardial dysfunction in asymptomatic individuals. What was learned from the MESA study? Page 7 ı4:40-ı4:55 ı4:55-ı5:25 Thomas Weiss, Oslo University Hospital Ullevål, Norway Expression of inflammation in adipose tissue as related to cardiovascular disease Thomas F. Lüscher, University Hospital Zürich, Switzerland Endothelial dysfunction in heart failure

Program OCTOBER ı, 20ı0 Session E: 08:30-09:ı0 09:ı0-09:40 09:40-ı0:05 Signaling in cardiac disease Chairs: Håvard Attramadal, OUHR, UoO and Finn Olav Levy, UoO Thomas Force, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Re-defining the role of the GSK-3 family in hypertrophy, post-mi remodeling, beta-adrenergic responsiveness, and cardiomyocyte proliferation in the adult heart Martin J. Lohse, University of Würzburg, Germany Cellular signaling in cardiac hypertrophy and failure Break _ Session F: ı0:05-ı0:45 ı0:45-ıı:00 ıı:00-ı2:00 Biomarkers and mechanisms of cardiac disease Chairs: Torbjørn Omland, AUH, UoO and Guro Valen, UoO James Louis Januzzi, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA Soluble ST2: Impact in cardiovascular disease? M. Shakil Ahmed, Oslo University Hospital Rikshospitalet, Norway Mechanisms of cardioprotection and myocardial repair - role of matricellular CCN2/CTGF Lunch _ Session G: Arrhythmias and cardiac resuscitation Chairs: Ole M. Sejersted, OUHU, UoO and Petter Andreas Steen, OUHU, UoO ı2:00-ı2:40 Yoram Rudy, Washington University in St. Louis, Missouri, USA The molecular basis of cardiac action potential repolarization OUHU OUHR OUHA AUH UoO UoT NTNU Oslo University Hospital, Ullevål Oslo University Hospital, Rikshospitalet Oslo University Hospital, Aker Akershus University Hospital University of Oslo University of Tromsø Norwegian University of Science and Technology, Trondheim ı2:40-ı2:55 ı2:55-ı3:ı0 ı3:ı0-ı3:40 _ Mathis K. Stokke, Oslo University Hospital Ullevål, Norway Mechanisms underlying non-reentrant ventricular arrhythmias in heart failure Theresa Olasveengen, Oslo University Hospital Ullevål, Norway Intravenous drugs during cardiac arrest Break Session H: Mechanisms of heart failure Chairs: Lars Gullestad, OUHR, UoO and Erik Øie, OUHR, Diakonhjemmet Hospital ı3:40-ı4:20 Heikki Ruskoaho, University of Oulu, Finland Molecular mechanisms of cardiac hypertrophy and heart failure Page 8 ı4:20-ı4:35 ı4:35-ı5:ı5 ı5:ı5-ı5:30 Johannes Bjørnstad, Oslo University Hospital Ullevål, Norway The novel ALK4/5 inhibitor SMı6 preserves cardiac function during pressure overload Douglas F. Larson, University of Arizona, Tucson, Arizona, USA Immune mechanisms associated with arterial hypertension and diastolic dysfunction Presentation of poster prize winners

Poster session I Inflammatory mediators and extracellular matrix in heart failure P0ı: Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction - potential counteracting effects of activin A on inflammation Andersen GØ, Ueland T, Knudsen EC, Scholz H, Yndestad A, Sahraoui A, Smith C, Lekva T, Otterdal K, Halvorsen B, Seljeflot I, Aukrust P P02: Adipose tissue expression of interleukin-ı8 is elevated in metabolic syndrome and independently associated with fasting glucose Weiss TW, Arnesen H, Trøseid M, Kaun C, Hjerkinn EM, Huber K, Wojta J, Seljeflot I P03: Effects of IL-ı8 neutralization in alveolar hypoxia Hillestad V, Larsen KO, Sjaastad I, Nygård S, Skjønsberg OH, Christensen G P04: Identification and characterization of the NLRP3 inflammasome in cardiac fibroblasts Sandanger Ø, Ranheim T, Vinge LE, Florholmen G, Christensen G, Dahl CP, Askevold E, Finsen AV, Rashidi A, Espevik T, Aukrust P, Yndestad A P05: Effects of exercise training on inflammatory markers in chronic heart failure - does etiology matter? Byrkjeland R, Nilsson BB, Westheim AS, Arnesen H, Seljeflot I P06: Proteomic profiling of skeletal muscle and serum from rats with genetically determined high and low VO 2max Bye A, Beisvåg V, Høydal M, Johnsen AB, Alves M, Koch L, Britton S, Wisløff U P07: Reduction in collagen VIII might be involved in transition from compensated hypertrophy to overt heart failure in pressure overload Skrbic B, Bjørnstad JL, Marstein HS, Sjaastad I, Nygård S, Christensen G, Tønnessen T P08: The influence of genetic variations on circulating levels of matrix metalloproteinase-9 in patients with cardiovascular disease Opstad TB, Pettersen AÅ, Åkra S, Weiss T, Arnesen H, Seljeflot I P09: Echocardiographic assessment of the area at risk in mice Redfors B, Scharin Tang M, Miljanovic A, Omerovic E Page 9

Poster session II Cellular signaling; myocardial hypertrophy and ischemia Pı0: Integrating microarray gene expression data with prior knowledge about molecular interactions for identification of important heart failure pathways Nygård S, Nygaard V, Clancy T, Bjørnstad J, Skrbic B, Sjaastad I, Tønnessen T, Christensen G, Hovig E Pıı: The Z-disc protein syndecan-4 activates pro-hypertrophic calcineurin-nfat signaling in the myocardium Lunde IG, Finsen AV, Jarstadmarken HO, Kvaløy H, Hasic A, Sjaastad I, Tønnessen T, Skrbic B, Wilcox-Adelman SA, Carlson CR, Christensen G Pı2: Mechanical Stress Increases NFAT Activity During the Hypertrophic Response in Isolated Cardiomyocytes from Neonatal Mice G. Florholmen, I.G. Lunde, C.R. Carlson, G. Christensen Pı3: Mechanical stretch activates the NFAT signaling pathway in cardiac fibroblasts Møller K, Florholmen G, Lunde IG, Behmen D, Carlson CR, Christensen G Pı4: De-phosphorylation - a matter of Phosphatase Specificity Cathrine Husberg, Giulio Agnetti, Geir Christensen, Jennifer Van Eyk Pı5: Protecting the heart through delivering DNA encoding for hemoxygenase-ı in skeletal muscle Bilbija D, Gravning J, Attramadal H, Valen G Pı6: Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure Jørgen Gravning, Stein Ørn, Thor Edvardsen, Vladimir N. Martinov, Cord Manhenke, Kenneth Dickstein, Håvard Attramadal and Mohammed Shakil Ahmed Pı7: New function of Matricellular Protein CCN2/CTGF as Proliferative and Survival Factor for Cardiac Stem Cells. Vladimir N Martinov A, M. Shakil Ahmed, Einar O Vik-Mo, David Kunke, Magnar Bjørås, Håvard Attramadal Pı8: CCN2 Exerts Direct Cytoprotective Actions on Cardiac Myocytes by Activation of the PI3-Kinase/Akt/GSK-3β Signaling Cascade Ingvild Tronstad Moe, Tuyet Anh Pham, M. Shakil Ahmed and Håvard Attramadal Pı9: Mechanisms of attenuated hypertrophic responses to chronic infusion of angiotensin II in Tg-CTGF mice Pham TA, Moe IT, von Lueder T, Ahmed MS, Attramadal H Page 10

Poster session III Cellular signaling; myocardial dysfunction P20: The NO/cyclic GMP signalling pathway differentially affects 5-HT 4 - and β ı -AR-mediated inotropic responses in failing ventricle Qvigstad E, Afzal F, Aronsen JM, Moltzau LR, Sjaastad I, Skomedal T, Osnes J-B, Levy FO P2ı: Compartmentation of the cgmp signal causes differential functional responses after CNP and BNP stimulation in failing myocardium Moltzau LR, Aronsen JM, Meier S, Nguyen CHT, Afzal F, Sjaastad I, Skomedal T, Osnes J-B, Levy FO, Qvigstad E P22: C-type natriuretic peptide signalling through NPR-B enhances the β ı -AR signalling both in non-failing and failing rat hearts Meier S, Aronsen JM, Levy FO, Skomedal T, Osnes J-B, Qvigstad Eı P23: Full length cardiac Na + -Ca 2+ exchanger (NCXı) protein is not phosphorylated by protein kinase A (PKA) Wanichawan P, Louch W, Austbø B, Scott JD, Sejersted OM and Carlson CR P24: Alterations in Ca 2+ Sparks and T-tubules Promote Slowed, Dyssynchronous Ca 2+ Release in Chronically Failing Cardiomyocytes Louch WE, Mørk HK, Hougen K, Sjaastad I, and Sejersted OM P25: Slowed cardiomyocyte Ca 2+ release during early heart failure results from alterations in Ca 2+ sparks Jølle GF, Skrbic B, Sjaastad I, Sejersted OM, and Louch WE P26: T-tubule proliferation facilitates trans-sarcolemmal Ca 2+ flux to compensate for declining SR function in Serca2 KO mice Swift F, Enger UH, Jølle GF, Andersson KB, Christensen G, Sejersted OM, and Louch WE P27: Increased oxygen cost for contractile function and decreased oxygen cost for excitation-contraction coupling in mice with inducible cardiomyocyte-specific excision of the Serca2 gene Neoma Boardman, Ole Sejersted, Ivar Sjaastad, Terje S Larsen, Geir Christensen, Ellen Aasum P28: Single dose tamoxifen for Cre-lox gene inactivation minimizes unspecific transcriptional changes and cardiomyopathy in mice. Karina Hougen, Jan Magnus Aronsen, Mathis K. Stokke, Ulla Enger, Ståle Nygård, Kristin B. Andersson, Geir Christensen, Ole M. Sejersted, Ivar Sjaastad P29: Characterization of factors regulating beta 2 -adrenoceptor-mediated contractility in human and rat left ventricle Hussain RI, Melsom CB, Nguyen CH, Qvigstad E, Skomedal T, Osnes JB, Levy FO, Krobert KA Page 11 P30: Prostanoid-mediated inotropic effects are attenuated in failing human and rat ventricular myocardium Riise J, Nguyen C, Hussain RI, Dahl CP, Ege MS, Osnes JB, Skomedal T, Sandnes D, Levy FO & Krobert KA

Poster session IV Cardiac imaging and arrhythmias P3ı: No Impact of Atrial Fibrillation on Mortality Risk in Optimally Treated Heart Failure Patients Tveit A, Flønæs B, Aaser E, Korneliussen K, Frøland G, Gullestad L, Grundtvig M P32: Asymmetric Dimethylarginine, Angiotensin Receptor Blockade and Endothelial Recovery after Electrical Cardioversion for Atrial Fibrillation Tveit A, Arnesen H, Smith P, Bratseth V, Seljeflot I P33: Mechanical dispersion and ventricular dysfunction by myocardial strain is related to malignant arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy Kristina Hermann Haugaa, Sebastian Imre Sarvari, Ole Gunnar Anfinsen, Otto A. Smiseth, Erik Kongsgård, Jan P. Amlie, Thor Edvardsen P34: High rate of successful left ventricle lead placement in the target wall region in standard CRT- implantation Köpp U, Gjestvang FT, Eivindson G, Myhre ESP P35: Low rates of left ventricle lead failure by adequate lead selection in CRT-implantation Köpp U, Gjestvang FT, Eivindson G, Myhre ESP P36: Prevalence of Cardiac Arrhythmias in Subjects with Obstructive Sleep Apnea in the General Population: The Akershus Sleep Apnea Project (ASAP) Namtvedt SK, Randby A, Einvik G, Somers VK, Røsjø H, Omland T P37: Cardiac dysfunction in juvenile dermatomyositis Thomas Schwartz, Helga Sanner, Trygve Huseby, Berit Flatø, Ivar Sjaastad P38: Prognostic significance of microvascular obstruction on left ventricular function and infarct size in patients with acute myocardial infarction Shanmuganathan L, Eritsland J, Andersen GØ, Kløw N-E and Hoffmann P P39: Early signs of LV deterioration in an experimental model of sepsis Hestenes S, Skulstad H, Halvorsen PS, Edvardsen T P40: Preserved Sublingual Microcirculation and Compensatory Up-regulated Liver and Kidney Mitochondrial Respiration in Pigs with Myocardial Ischemia and Cardiogenic Shock Kildal A, Sanden E, Stenberg T, How O-J, Chi X, Hagve M, Ytrehus K, Larsen T, Hermansen S and Myrmel T Page 12

Poster session V Markers of cardiovascular disease P4ı: Circulating secreted frizzled related protein 3 (sfrp3) predicts outcome in patients with chronic heart failure Askevold ET, Dahl CP, Broch K, Aakhus S, Yndestad A, Gullestad L, Aukrust P, Ueland T P42: Plasma levels of Wnt inhibitory factor-ı (WIF-ı) are elevated and predict mortality in symptomatic aortic stenosis Erik Tandberg Askevold, Lars Gullestad, Svend Aakhus, Ole G. Solberg, Pål Aukrust, Thor Ueland P43: N-terminal pro-b-type natriuretic peptide is associated with the incidence of sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function Røysland R, Omland T, Sabatine MS, Hsia J, Solomon SD, Christophi CA, Rice MM, Jablonski KA, Domanski MJ, Rouleau JL, Pfeffer MA, Braunwald E, for the PEACE Investigators P44: Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, Di Tano G, Maggioni AP, Tavazzi L, Latini R, on behalf of the GISSI-HF Investigators. P45: Elevated serum osteoprotegerin levels measured early after an acute ST-elevation myocardial infarction predicts final infarct size. Andersen GØ, Knudsen EC, Aukrust P, Yndestad A, Øie E, Müller C, Seljeflot I, Ueland T P46: The Influence of Intracoronary Injection of Mononuclear Bone Marrow Cells on Prothrombotic Markers in Patients with Acute Myocardial Infarction Solheim S, Seljeflot I, Lunde K, Aakhus S, Bratseth V, Forfang K, Arnesen H P47: Prothrombotic Markers in Patients with Acute Myocardial Infarction and Left Ventricular Thrombus Formation Treated with Dual Antiplatelet Therapy Solheim S, Arnesen H, Lunde K, Aakhus S, Bjørnerheim R, Bratseth V, Forfang K, Seljeflot I P48: Circulating PAI-ı activity and t-pa antigen are associated with newly diagnosed abnormal glucose regulation in patients with acute STEMI. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, Andersen GØ P49: Prognostic value of oral glucose tolerance testing in patients with a primary PCI treated STEMI. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, Andersen GØ Page 13 P50: Predictors of Troponin Elevation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Høiseth AD, Neukamm A, Brekke PH, Omland T, Søyseth V P5ı: Elevated level of Aldosterone during acute exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) predicts post discharge mortality. Høiseth AD, Neukamm A, Brekke PH, Omland T, Søyseth V